Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/11/2018 |
| Start Date: | April 9, 2018 |
| End Date: | December 2021 |
| Contact: | TG Therapeutics Clinical Support Team |
| Email: | clinicalsupport@tgtxinc.com |
| Phone: | 212-554-4484 |
This study will be a standard 3+3 design with a lead in of umbralisib (TGR-1202) +
ublituximab for 12 weeks, i.e. 3 cycles, followed by venetoclax (20 mg - 200 mg) along with
umbralisib (TGR-1202) and ublituximab for patients with relapsed/refractory CLL.
ublituximab for 12 weeks, i.e. 3 cycles, followed by venetoclax (20 mg - 200 mg) along with
umbralisib (TGR-1202) and ublituximab for patients with relapsed/refractory CLL.
Inclusion Criteria:
- Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia
- Refractory to or relapsed after at least 1 prior treatment regimen
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Exclusion Criteria:
- Any major surgery, chemotherapy or immunotherapy within the last 21 days
- Known hepatitis B virus, hepatitis C virus or HIV infection
- Known histological transformation from CLL to an aggressive lymphoma (Richter's)
We found this trial at
2
sites
Cleveland Clinic Taussig Cancer Center At Taussig Cancer Institute, more than 250 highly skilled doctors,...
Click here to add this to my saved trials
Click here to add this to my saved trials